Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 7/20 | 0.40 |
| ▸ | PTGES | O14684 | 1/20 | 0.40 |
| ▸ | PNLIP | P16233 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | GGPS1 | O95749 | 4/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22861902 | 0.78 | — | — | |
| SCHEMBL31238108 | 0.78 | FDPS (0.61) | FDPSPTGESPNLIPMEN1KMT2A | |
| Rosmanol SCHEMBL13062163 | 0.68 | FDPS (0.65) | FDPSPTGESPNLIPMEN1KMT2A | |
| Epirosmanol SCHEMBL3272202 | 0.68 | FDPS (0.65) | FDPSPTGESPNLIPMEN1KMT2A | |
| Epirosmanol SCHEMBL29426648 | 0.68 | FDPS (0.65) | FDPSPTGESPNLIPMEN1KMT2A | |
| Rosmanol SCHEMBL459610 | 0.68 | FDPS (0.65) | FDPSPTGESPNLIPMEN1KMT2A | |
| Rosmanol SCHEMBL28962181 | 0.68 | FDPS (0.65) | FDPSPTGESPNLIPMEN1KMT2A | |
| SCHEMBL29385649 | 0.67 | FDPS (0.64) | FDPSPTGESPNLIPMEN1KMT2A | |
| Taiwaniaquinol C SCHEMBL31237206 | 0.65 | PIK3CA (0.33) | FDPSMEN1KMT2AGGPS1 | |
| Taiwaniaquinol B SCHEMBL31237215 | 0.63 | USP2 (0.37) | FDPSPTGESPNLIPMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210000841-A1 | COMPOUNDS THAT MODULATE VON WILLEBRAND FACTOR LEVELS AND THEIR USE IN THE TREATMENT OF BLOOD DISORDERS | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2021-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210000841-A1 | COMPOUNDS THAT MODULATE VON WILLEBRAND FACTOR LEVELS AND THEIR USE IN THE TREATMENT OF BLOOD DISORDERS | F5, F2, F3 | FDPS 124/4885PTGES 247/4885PNLIP 933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.